IL-18 Engineering & Application Development Services
Creative Biolabs' service is meticulously designed to transform the potent but clinically challenging interleukin-18 (IL-18) into a safe, high-efficacy therapeutic agent. We provide solutions grounded in cutting-edge molecular engineering, specifically addressing two primary obstacles to clinical success: the high-affinity neutralization by the endogenous trap, IL-18 binding protein (IL-18BP), and the pervasive risk of systemic toxicity caused by non-specific immune activation. By engineering targeted IL-18 variants, we ensure maximal anti-tumor effect while maintaining systemic safety, significantly improving the therapeutic index.
Background Featured Services What We Can Offer Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
The Critical Challenges of Wild-Type IL-18
The efficacy and safety of native recombinant IL-18 are primarily limited by four factors. Firstly, potent neutralization occurs via IL-18BP, a high-affinity antagonist circulating in molar excess that acts as a systemic "buffer." Secondly, a short in vivo half-life leads to rapid clearance, preventing sustained T and NK cell functions. Thirdly, unfavorable physicochemical properties result in poor stability and low production yields, hindering manufacturing. Finally, the risk of systemic toxicity (e.g., CRS) from widespread receptor activation necessitates new engineering strategies to confine IL-18 activation to the tumor microenvironment (TME).
Our Featured Services
Overcoming IL-18BP Inhibition
Creative Biolabs offers the definitive overcoming IL-18BP inhibition service. We use advanced molecular engineering to create IL-18 variants that evade the natural IL-18BP trap, ensuring superior tumor efficacy and safety.
Learn More →
Key Solutions and Deliverables You Can Expect
Decoy-Resistant IL-18 Muteins
Delivery of novel IL-18 variants with strategically engineered amino acid substitutions that significantly reduce binding affinity to IL-18BP while retaining or enhancing full agonistic activity towards the IL-18 receptor.
TME-Regulated Activation Systems
Design and synthesis of pro-cytokines that are only activated in the TME via mechanisms like granzyme B (GzB) cleavage or pH-sensitive linkers, ensuring localized efficacy and minimizing systemic toxicity.
Molecular Mechanism Mapping
Comprehensive analysis using our proprietary genomic data to identify novel IL-18 regulatory pathways in cancer, metabolism, and the central nervous system, broadening the application potential of your therapeutic.
Contact us today to schedule a confidential consultation and learn how our 20+ years of protein engineering expertise can unlock the full, sustained therapeutic power of IL-18 for your pipeline.
Workflow: From Design to Optimized Candidate
Our process is structured to provide clarity and efficiency, ensuring a rapid transition from initial concept to a validated therapeutic candidate.
Publication
IL-18 is a promising cytokine for immunotherapy, but its efficacy can be limited. Engineering strategies have primarily targeted their receptor-binding sites. This study investigates a non-binding residue, Threonine 63 (T63), which significantly enhances activity when mutated alongside E6K. Using molecular dynamics simulations, we reveal that T63 acts as a structural hub, remotely controlling the flexibility of distant binding sites through a key hydrogen-bond network. Our findings establish the rational engineering of non-binding residues as a powerful strategy for developing potent IL-18 therapeutics.
Fig.1 Architecture of the IL-18 signaling complex. 1
Why Choose Us?
Creative Biolabs is a leader in cytokine engineering, delivering clinically superior IL-18 therapeutics by merging advanced protein design with proprietary insights. Our core advantages include proprietary IL-18BP evasion technology to guarantee functional circulation and TME reach. We offer best-in-class safety profiling using our granzyme B-activated IL-18 technology, which tightly couples cytokine activity to CAR T-cell/NK cell engagement, virtually eliminating systemic cytokine release syndrome (CRS). We leverage deep molecular insight into IL-18's regulatory roles (e.g., STAT3, Erdr1) to design therapeutics with reduced off-target liabilities.
Experience the Creative Biolabs Advantage - Get a Quote Today to see the difference our expertise can make in your project.
FAQs
Q1: How does your approach compare to simply co-administering IL-18 with IL-18BP-blocking antibodies?
A1: Our candidates possess intrinsic resistance, ensuring sustained therapeutic efficacy without the need for co-administration of a second therapeutic antibody, simplifying manufacturing and reducing development costs.
Q2: Can your engineered IL-18 be used to enhance the activity of adoptive cell therapies (ACTs) like TILs or NK cells?
A2: Absolutely. Our decoy-resistant mutants and TME-regulated variants are ideal for enhancing the function, persistence, and metabolic fitness of all ACT modalities, including TILs and NK cells, via autocrine or paracrine signaling.
Q3: Is it possible to combine your IL-18 engineering service with a tumor-targeting antibody to create an immunocytokine?
A3: We strongly encourage this strategy. We offer comprehensive immunocytokine development services where we fuse the optimized IL-18 mutein to your tumor-specific antibody (e.g., anti-TAA).
Customer Reviews
-
Exceptional IL-18BP Resistance
Using Creative Biolabs' services in our research has significantly improved the in vivo persistence of our candidate by eliminating IL-18BP neutralization, which was the primary limitation of our previous versions. – Mara*Mendoa
-
Precise TME-Specific Activation
The GzB-activated pro-cytokine approach provided a crucial solution for safely arming our TCR-T cells. We saw a dramatic reduction in off-target systemic inflammation compared to constitutively active IL-18 variants, which is a key advantage for our solid tumor clinical strategy. - Dr. Tm*Hnter
Related Services
Creative Biolabs offers a full suite of services complementary to our IL-18 engineering platform, allowing for an integrated development pipeline.
Cytokine Production Measurement Service
Creative Biolabs measures cytokine production using FC, ELISA, IHC, PCR, and IF with advanced instruments to better understand dysregulated cytokines in the TME.
Learn More →
Engineering Liver Cancer Cells for Self-destruction
Creative Biolabs generates synthetic gene circuits that locally and accurately produce immunomodulators exclusively in targeted cancer cells, enabling enhanced, specific cancer therapy.
Learn More →
How to Contact Creative Biolabs
Creative Biolabs is dedicated to eliminating the clinical limitations of IL-18 by providing truly next-generation therapeutics. Our integrated approach—combining decoy-resistant mutein design, TME-regulated activation, and deep molecular insights—ensures your IL-18 program is built on a foundation of superior efficacy and safety, accelerating your path to the clinic.
Contact Our Team for More Information and to Discuss Your Project
Reference
-
Peeyatu, Chariya, et al. "Role of Non-Binding T63 Alteration in IL-18 Binding." International Journal of Molecular Sciences 25.23 (2024): 12992. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms252312992
